Structure, which concentrates on metabolic diseases with a particular focus on obesity, unveiled the topline data for its GLP-1 drug aleniglipron. The weight-loss treatment was put through its paces ...

Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety ...

Hedge fund BVF increased its GPCR holding by 275,105 shares in the fourth quarter; the estimated trade value was $11.2 million based on quarterly average prices. Meanwhile, the quarter-end position ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...